W. Geitzenauer
About
In The Last Decade
W. Geitzenauer
42 papers receiving 1.7k citations
Peers
Comparison fields: 5 of 64
- Ophthalmology 1.5k
- Radiology, Nuclear Medicine and Imaging 1.1k
- Biomedical Engineering 488
- Molecular Biology 169
- Biophysics 108
Countries citing papers authored by W. Geitzenauer
This map shows the geographic impact of W. Geitzenauer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by W. Geitzenauer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites W. Geitzenauer more than expected).
Fields of papers citing papers by W. Geitzenauer
This network shows the impact of papers produced by W. Geitzenauer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by W. Geitzenauer. The network helps show where W. Geitzenauer may publish in the future.
Co-authorship network of co-authors of W. Geitzenauer
This figure shows the co-authorship network connecting the top 25 collaborators of W. Geitzenauer. A scholar is included among the top collaborators of W. Geitzenauer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with W. Geitzenauer. W. Geitzenauer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 4 | |
| 2 | 18 | |
| 3 | 4 | |
| 4 | 2 | |
| 5 | Polarization-Sensitive Optical Coherence Tomography in Adult-Onset Foveomacular Vitelliform Dystrophy | 0 |
| 6 | 43 | |
| 7 | 47 | |
| 8 | Intravitreal Bevacizumab (Avastin®) Monotherapy versus Photodynamic Therapy Plus Intravitreal Triamcinolone for Neovascular Age-Related Macular Degeneration:12 Months Results of a Prospective, Randomized, Controlled Clinical Trial | 2 |
| 9 | 7 | |
| 10 | 11 | |
| 11 | 223 | |
| 12 | 157 | |
| 13 | Intravitreal Bevacizumab (Avastin®) Therapy versus Verteporfin Therapy and Intravitreal Triamcinolone for Neovascular Age-Related Macular Degeneration | 1 |
| 14 | 24 | |
| 15 | Standard vs. Reduced Dose Systemic Bevacizumab (Avastin®) for the Treatment of Neovascular Age–Related Macular Degeneration | 2 |
| 16 | VEGF 165 Serum Levels Following Systemic Bevacizumab (Avastin®) Therapy for Neovascular Age–Related Macular Degeneration | 1 |
| 17 | Anterior Chamber Inflammatory Activity in Patients With Neovascular Age–Related Macular Degeneration Treated With Intravitreal Bevacizumab (Avastin®) | 1 |
| 18 | Comparison of Early Response to Systemic or Intravitreal Bevacizumab (Avastin®) in Patients With Neovascular AMD | 1 |
| 19 | 53 | |
| 20 | 28 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.